E1609 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma

Cancer - Melanoma

All patients must have disease that is completely surgically resected in order to be eligible; patients must have been surgically rendered free of disease with negative margins on resected specimen; patients rendered free of disease by non-surgical means are not eligible. Patients with unknown primary melanoma (Tx) who present with cutaneous, subcutaneous, nodal and/or lung metastases that are completely surgically resected with free margins are allowed; these patients are allowed even if they don't fit the strict staging criteria. Please call for further eligibility criteria.

Tiffany Pearce